Funding news · Nov 12, 2026
Orakl Oncology Raises $34M Series A Led by Norrsken VC
Orakl Oncology Closes $34M Series A
Orakl Oncology, a developer of a drug-testing platform for oncology, has raised $34 million in Series A funding. The round was led by Norrsken VC.
What Orakl Oncology Does
Orakl Oncology builds a drug-testing platform that models how cancer patients respond to therapies. The platform uses patient-derived biology to create virtual representations of tumors. Pharmaceutical teams use it to predict treatment response and de-risk oncology development programs before human trials.
Funding Details
- Round: Series A
- Amount: $34 million USD
- Lead Investor: Norrsken VC
- Date: November 12, 2026
Investor Syndicate
The Series A included participation from a broad group of investors:
- InfraVia
- Bpifrance
- Speedinvest
- Verve Ventures
- Serena (lead, via InnovAllianz III)
- Plug and Play Tech Center
- Norrsken VC
- Singular
- HCVC
- Teampact Ventures
Strategic Context
The Series A provides Orakl Oncology with capital to advance its patient-derived tumor modeling platform. By enabling pharmaceutical teams to predict treatment response before human trials, the company addresses a key challenge in oncology drug development: reducing the risk and cost of late-stage failures.
For acquisition-oriented observers, Orakl Oncology represents a platform positioned at the intersection of computational biology and oncology drug development, with a syndicate that includes both European and international investors.